Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration [ Time Frame: Baseline up to study completion (estimated at 10 weeks) ] [ Designated as safety issue: Yes ]

Pharmacokinetics: Area Under the Concentration Curve (AUC) of LY2922470 [ Time Frame: Baseline up to 48 hours post dose of study drug on Day 1 and Day 28 ] [ Designated as safety issue: No ]

Pharmacokinetics: Maximum Concentration (Cmax) of LY2922470 [ Time Frame: Baseline up to 48 hours post dose of study drug on Day 1 and Day 28 ] [ Designated as safety issue: No ]

Pharmacokinetics: Time to Maximum Concentration (Tmax) of LY2922470 [ Time Frame: Baseline up to 48 hours post dose of study drug on Day 1 and Day 28 ] [ Designated as safety issue: No ]

Change from Baseline in Hemoglobin A1c (HbA1c) [ Time Frame: Baseline, up to Day 28 ] [ Designated as safety issue: No ]

Change from Baseline in Blood Glucose Area Under the Effective Concentration Curve (AUEC) During Mixed Meal Tolerance Test [ Time Frame: Baseline, up to 2.5 hours post dose of study drug on Day 28 ] [ Designated as safety issue: No ]

Change from Baseline in C-Peptide Area Under the Effective Concentration Curve (AUEC) During Mixed Meal Tolerance Test [ Time Frame: Baseline, up to 2.5 hours post dose of study drug on Day 28 ] [ Designated as safety issue: No ]

The main purpose of this study is to determine the safety of LY2922470, taken as oral capsules, once or twice daily for approximately 28 days, in participants with diabetes. It also aims to determine how long the drug stays in the body and how it affects blood sugar levels. A screening appointment is required within 28 days before the start of the study and a follow up appointment is required approximately 14 days after the last study dose is taken.

Are currently participating in another clinical study or completed one in the last 30 days

Have a history of significant heart, lung, liver, kidney, stomach or brain disease, or have any medical problems which may cause an increased risk during the study

Have electrocardiogram (ECG) readings that are not suitable for the study

Are infected with hepatitis B or hepatitis C

Are infected with human immunodeficiency virus (HIV)

Have donated blood equal to or more than 500 mL within 56 days before the first dose of drug or have donated plasma within 7 days before the first dose or provided any blood donation within the last month from screening

Gender

Both

Ages

18 Years to 70 Years

Accepts Healthy Volunteers

No

Contacts ICMJE

Contact information is only displayed when the study is recruiting subjects